Following Charles Berkman’s last LGND Buy transaction on August 10, 2017, the stock climbed by 80.7%. This is Berkman’s first Buy trade following 7 Sell transactions.
Based on Ligand Pharma’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $90.04 million and quarterly net profit of $73.16 million. In comparison, last year the company earned revenue of $33.38 million and had a net profit of $8.43 million. LGND’s market cap is $4.34B and the company has a P/E ratio of 41.81. Currently, Ligand Pharma has an average volume of 1.28M.
Based on 6 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $265.67, reflecting a 31.1% upside. Four different firms, including Argus Research and Craig-Hallum, currently also have a Buy rating on the stock.
The insider sentiment on Ligand Pharma has been negative according to 70 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.